Clinical Trial Update: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations [Phase 1]

View source ↗

Summary

Phase 1 study of KIN-3248 in FGFR2/3-altered advanced tumors was terminated. The trial enrolled patients with intrahepatic cholangiocarcinoma and urothelial car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma
• Urothelial Carcinoma

Drugs mentioned

• KIN-3248

Snippet

Sponsor: Kinnate Biopharma | Conditions: Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma | Phase 1 | Status: TERMINATED